Pharm
Apixaban
search
Apixaban
, Eliquis
See Also
Direct Oral Anticoagulant
Anticoagulation
Rivaroxaban
Edoxaban
Fondaprinux
Dabigatran
Heparin
Warfarin
Mechanism
Oral direct Xa inhibitor
Factor X
a is the first step in the
Common Clotting Cascade
Indications
Venous Thromboembolism
or its prophylaxis
Heparin Induced Thrombocytopenia
(not FDA approved)
Nonvalvular
Atrial Fibrillation
(stroke prevention with
CHADS Score
2 or more)
First-line alternative to
Warfarin
Poor INR control on
Warfarin
Barriers to INR monitoring
Warfarin Drug Interactions
Contraindications
Acute bleeding
Initial studies suggest less bleeding risk than
Warfarin
Mechanical Heart Valve
s or valvular
Atrial Fibrillation
Use
Warfarin
instead
Moderate to severe hepatic
Impairment
Pregnancy or
Lactation
Precautions
Emergent Reversal of Anticoagulation
(e.g.
Hemorrhage
)
Andexxa
released in 2018
Consider
Prothrombin Complex Concentrate
, activated PCC or recombinant
Factor VII
a
Increased stroke risk if stopped abruptly without other
Anticoagulation
in nonvalvular
Atrial Fibrillation
Pharmacokinetics
Half-Life
: 8-15 hours (12 hour mean)
Oral
Bioavailability
: 58%
Onset: 3-4 hours
Dosing
Atrial Fibrillation
Standard dose
Apixaban (Eliquis) 5 mg twice daily
Half-dose indications (2.5 mg twice daily)
See
Renal Dosing
below
Dosing
Venous Thromboembolism
Renal Dosing
does not apply
Venous Thromboembolism
Treatment
Initial: 10 mg orally twice daily for 7 days
Maintenance: 5 mg orally twice daily
Prevention of recurrence: 2.5 mg orally twice daily
Venous Thromboembolism
Prophylaxis after Surgery
Hip Replacement: 2.5 mg orally twice daily for 35 days
Knee
Replacement: 2.5 mg orally twice daily for 12 days
Acute
Heparin Induced Thrombocytopenia
(not FDA approved)
Take 5 mg orally twice daily (until
Platelet Count
s return to normal)
If thrombosis is present, start with 10 mg orally twice daily for 1 week
Dosing
Renal Dosing
Indications
Applies only to
Atrial Fibrillation
(not to
Venous Thromboembolism
)
Renal Dosing
(2.5 mg orally twice daily) is indicated if at least 2 of the following criteria are present
Serum Creatinine
>=1.5 mg/dl or higher
Age >=80 years old
Weight <=60 kg (or <132 lb)
References
https://packageinserts.bms.com/pi/pi_eliquis.pdf
Drug Interactions
Strong
Cytochrome P450
3A4 inducers
Rifampin
(also induces
P-Glycoprotein
)
Phenytoin
Carbamazepine
Phenobarbital
P-Glycoprotein Inhibitor
s
Ketoconazole
Itraconazole
Voriconazole
Ritonavir
Conivaptan
Clarithromycin
Dronedarone
Verapamil
Other
Anticoagulant
s and antiplatelet agents
Aspirin
and other antiplatelet agents (e.g.
Clopidogrel
)
NSAID
s
Safety
Unknown Safety in Pregnancy
Unknown Safety in
Lactation
Resources
Apixaban (DailyMed)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=095a08ac-cf0e-497e-a682-ddef38d6b29c
References
(2014) Presc Lett 21(11): 61
Granger (2011) N Engl J Med 365(11): 981-92 [PubMed]
Connolly (2011) N Engl J Med 364(9): 806-17 [PubMed]
Wilbur (2017) Am Fam Physician 95(5): 295-302 [PubMed]
Wigle (2019) Am Fam Physician 100(7): 426-34 [PubMed]
Type your search phrase here